Cell Proliferation 2012-12-01

Oridonin: targeting programmed cell death pathways as an anti-tumour agent.

Z Liu, L Ouyang, H Peng, W-Z Zhang

Index: Cell Prolif. 45(6) , 499-507, (2012)

Full Text: HTML

Abstract

Oridonin, an active diterpenoid isolated from traditional Chinese herbal medicine, has drawn rising attention for its remarkable apoptosis- and autophagy-inducing activity and relevant molecular mechanisms in cancer therapy. Apoptosis is a well known type of cell death, whereas autophagy can play either pro-survival or pro-death roles in cancer cells. Accumulating evidence has recently revealed relationships between apoptosis and autophagy induced by oridonin; however, molecular mechanisms behind them remain to be discovered. In this review, we focus on highlighting updated research on oridonin-induced cell death signalling pathways implicated in apoptosis and autophagy, in many types of cancer. In addition, we further discuss cross-talk between apoptosis and autophagy induced by oridonin, in cancer. Taken together, these findings open new perspectives for further exploring oridonin as a potential anti-tumour agent targeting apoptosis and autophagy, in future anti-cancer therapeutics.© 2012 Blackwell Publishing Ltd.


Related Compounds

  • Oridonin

Related Articles:

[Anti-tumor effect of tanshinone II A, tetrandrine, honokiol, curcumin, oridonin and paeonol on leukemia cell lines].

2012-05-01

[Sichuan Da Xue Xue Bao. Yi Xue Ban 43(3) , 362-6, (2012)]

Induction of human CYP3A4 by huperzine A, ligustrazine and oridonin through pregnane X receptor-mediated pathways.

2014-07-01

[Pharmazie 69(7) , 532-6, (2014)]

The anticancer effect of oridonin is mediated by fatty acid synthase suppression in human colorectal cancer cells.

2013-02-01

[J. Gastroenterol. 48(2) , 182-92, (2013)]

Nitric oxide augments oridonin-induced efferocytosis by human histocytic lymphoma U937 cells via autophagy and the NF-κB-COX-2-IL-1β pathway.

2012-10-01

[Free Radic. Res. 46(10) , 1207-19, (2012)]

Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway.

2012-09-01

[Int. J. Oncol. 41(3) , 949-58, (2012)]

More Articles...